These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1956988)

  • 1. The changes of thyroid hormone during pharmacological treatment of panic disorder patients.
    Balon R; Pohl R; Yeragani VK; Ramesh C; Glitz DA
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):595-600. PubMed ID: 1956988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.
    Balon R; Yeragani VK; Pohl R; Merlos B; Sherwood P
    Can J Psychiatry; 1993 Feb; 38(1):19-22. PubMed ID: 8448714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
    Modigh K; Westberg P; Eriksson E
    J Clin Psychopharmacol; 1992 Aug; 12(4):251-61. PubMed ID: 1527228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactate-induced anxiety after imipramine and diazepam treatment.
    Pohl R; Balon R; Berchou R; Lycaki H
    Anxiety; 1994; 1(2):54-63. PubMed ID: 9160549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
    Rynn M; García-España F; Greenblatt DJ; Mandos LA; Schweizer E; Rickels K
    J Clin Psychopharmacol; 2003 Oct; 23(5):505-8. PubMed ID: 14520129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.
    Rickels K; Downing R; Schweizer E; Hassman H
    Arch Gen Psychiatry; 1993 Nov; 50(11):884-95. PubMed ID: 8215814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
    Woods SW; Nagy LM; Koleszar AS; Krystal JH; Heninger GR; Charney DS
    J Clin Psychopharmacol; 1992 Feb; 12(1):32-8. PubMed ID: 1552038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between anxiety and thyroid function in patients with panic disorder.
    Kikuchi M; Komuro R; Oka H; Kidani T; Hanaoka A; Koshino Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):77-81. PubMed ID: 15610948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls.
    Roy-Byrne PP; Cowley DS; Hommer D; Greenblatt DJ; Kramer GL; Petty F
    Psychopharmacology (Berl); 1992; 109(1-2):153-6. PubMed ID: 1365649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo.
    Pollack MH; Otto MW; Sachs GS; Leon A; Shear MK; Deltito JA; Keller MB; Rosenbaum JF
    J Affect Disord; 1994 Apr; 30(4):273-81. PubMed ID: 8014326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of panic disorder.
    Cassano GB; Toni C; Musetti L
    Adv Biochem Psychopharmacol; 1992; 47():449-60. PubMed ID: 1509926
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects.
    Roy-Byrne P; Wingerson DK; Radant A; Greenblatt DJ; Cowley DS
    Am J Psychiatry; 1996 Nov; 153(11):1444-9. PubMed ID: 8890678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.
    Keller MB; Lavori PW; Goldenberg IM; Baker LA; Pollack MH; Sachs GS; Rosenbaum JF; Deltito JA; Leon A; Shear K
    J Affect Disord; 1993 May; 28(1):27-38. PubMed ID: 8326078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
    Sheikh JI; Swales PJ
    Int J Psychiatry Med; 1999; 29(1):107-17. PubMed ID: 10376237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.
    Rickels K; Chung HR; Csanalosi IB; Hurowitz AM; London J; Wiseman K; Kaplan M; Amsterdam JD
    Arch Gen Psychiatry; 1987 Oct; 44(10):862-6. PubMed ID: 3310952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
    Taylor CB; Hayward C; King R; Ehlers A; Margraf J; Maddock R; Clark D; Roth WT; Agras WS
    J Clin Psychopharmacol; 1990 Apr; 10(2):112-8. PubMed ID: 2187912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipramine-induced jitteriness and decreased serum iron levels.
    Yeragani VK; Pohl R; Balon R; Ramesh C; Weinberg P
    Neuropsychobiology; 1992; 25(1):8-10. PubMed ID: 1603294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.